Approval of aducanumab for Alzheimer’s disease

Medical management issues in dementia: recommendations

EAN guidance on managing patients with dementia

Therapeutic development in Alzheimer’s disease and the lack of funding

The benefits of GWAS in understanding Alzheimer’s disease

Cross neurodegenerative disease genetic analysis: similarities and differences

Dementia, stress and the molecular age of the brain

Identifying new therapeutic targets for neurodegenerative diseases

The future of Alzheimer’s disease: aducanumab

Dementia and stress: the challenges

Hopeful developments for Alzheimer’s Disease

Defining Alzheimer’s disease: clinical or biological

CT1812: exciting preliminary results

Therapeutics designed to mimic protective mutations for Alzheimer’s disease

A673T mutation lowers Aβ oligomer binding affinity: Alzheimer’s disease protective mechanism

The role of phosphorylated tau in clinical trials